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Molecular epidemiology has revealed that Mycobacterium tuberculosis (Mtb), formerly regarded as highly conserved species,
displays a considerable degree of genetic variability that can influence the outcome of the disease as well as the innate and adaptive
immune response. Recent studies have demonstrated thatMtb families found worldwide today differ in pathology, transmissibility,
virulence, and development of immune response. By proteomic approaches seven proteins that were differentially expressed
between a local clinical isolate from Latin-American-Mediterranean (LAM) and from Haarlem (H) lineages were identified. In
order to analyze the immunogenic ability, recombinant Rv2241, Rv0009, Rv0407, and Rv2624c proteins were produced for testing
specific antibody responses. We found that these proteins induced humoral immune responses in patients with drug-sensitive and
drug-resistant tuberculosis with substantial cross-reactivity among the four proteins. Moreover, such reactivity was also correlated
with anti-Mtb-cell surface IgM, but not with anti-ManLAM, anti-PPD, or anti-Mtb-surface IgG antibodies. Therefore, the present
results describe newMtb antigens with potential application as biomarkers of TB.
1. Introduction
Increasing evidence suggests that genetic variation in Myco-
bacterium tuberculosis (Mtb) plays an important role in the
outcome of the disease [1–3]. Owing to the lack of exchange of
genetic material with a global microbial gene pool, Mtb had
long been considered to have a clonal population structure.
However, a significant genetic variation within Mtb has
recently been unveiled by the identification of six phylogeo-
graphic lineages [2, 4, 5]. One of these lineages is the Euro-
American clade, which includes all the spoligotype families
predominating in theWestern world, such asHaarlem, Latin-
American-Mediterranean (LAM), and the not well-defined T
group [6]. In particular, the Haarlem genotype is ubiquitous
worldwide [7] and represents about 25% of the isolates in
Europe, Central America, and the Caribbean [8]. In South
America, the LAM family is the prevalent one, followed by the
T andHaarlem families [9, 10]. Very recently, we had reported
that in Buenos Aires area 37% of TB patients were infected
with LAM, 34% with T and 17% with Haarlem lineages
[11]. Recent epidemiological data suggest that differences in
transmissibility and virulence amongMtb strains are related
to the genetic background of the organism [12–14]. Particular
outbreak strains were found to elicit distinct immune paths
and mortality rates in the course of mice infection [15]. In
this line, Lo´pez et al. have demonstrated that mice infected
with Beijing strains show accelerated bacterialmultiplication,
early and massive pneumonia, and death. Conversely, infec-
tion with Canetti strains induces a slow progressive disease
characterized by delayed bacterial multiplication, limited
pneumonia, steadily increasing granulomas, and virtually no
mortality. In terms of virulence, strains belonging to two
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other conspicuous genotype families, the so-called Haarlem
and Somali clades, displayed rather intermediate and less
homogeneous results [14].
Antibody (Ab) responses strongly affect pathogenesis and
outcome of disease caused by extracellular bacteria. However,
Abs are also produced in infections caused by intracellular
bacteria, where protective immunity is primarily elicited by
the cell-mediated immune response [16]. In the case of tuber-
culosis (TB) the detection of circulating Abs in patients with
active TB dates back to 1898 [17]. Even though an estimated
90% of TB patients produce Abs against Mtb [18], little
is known about the correlation between their production,
specificity, and disease process. The evaluation of Abs as
biomarkers of active disease has been widely investigated
[18–20]. However, due to the variation in Ab profiles among
TB patients, their application as diagnostic tool has several
limitations [18, 21, 22]. Moreover, host associated variables
affecting Ab responses have been sporadically studied [23,
24].Thus, despitemuch effort, we still do not knowhowmuch
of theMtb proteome is targeted by the human Ab response or
how host characteristics and disease parameters affect target
recognition.
As a classical model of intracellular pathogen, the immu-
nity to Mtb is associated with a Th1-profile, in which the
interleukin- (IL-) 12-interferon- (IFN-) 𝛾 axis together with
tumor necrosis factor- (TNF-) -𝛼 is involved [25]. However,
recent studies have revealed that Mtb developed a more
complex host immune response [26]. It is well known that
the cell envelope ofMtb is composed of proteins intermingled
in a matrix of peptidoglycan, mycolic acids, lipids, and
carbohydrates driving a complex and diverse structure which
can influence the host immune response. We have previously
demonstrated that inactivated clinical isolates from LAM
and Haarlem families induced in vitro differential cytokine
and reactive oxygen species (ROS) production by cells from
innate and adaptive arms of the immune response in TB
patients and healthy donors [27–29]. Moreover, the immune
profiles seem to be associated with the families they belong to
and not with a special characteristic of the isolate, suggesting
that antigen composition might account for such differences
[27–29].
The aim of the current study was to analyze whether
the proteomic differences detected between the two clinical
isolates could be reflected at the level of Abs response. We
identified seven proteins that were differentially expressed
between the local clinical LAM isolate LAM10406 and the
Haarlem isolate H12425. Furthermore, Ab response against
four of these proteins was detected in drug-sensitive and
drug-resistant TB patients, showing cross-reactive humoral
responses in most of the cases.
2. Materials and Methods
2.1. Patients. TB patients were recruited at the Servicio
de Tisioneumonologı´a, Hospital F. J. Mun˜iz, Buenos Aires,
Argentina. Signed written informed consent was obtained
according to Ethics Committee from Hospital F. J. Mun˜iz.
Physical examination, serum extraction, complete blood cell
count, electrolyte, sputum bacilloscopy, chest X-ray, and HIV
testwere carried out in the same institution. Exclusion criteria
included positive HIV test, extrapulmonary dissemination of
TB, and presence of concurrent infectious diseases. Inclusion
criteria among TB patients were the presence of moderate
to severe pulmonary involvement according to chest X-ray
findings. Among enrolled TB patients (𝑛 = 37, average
age = 32 yr, range = 21–55 yr), 18 had multi-drug-resistant
(MDR) TB with severe pulmonary involvement, and among
drug-sensitive TB, 11 had severe and 9 moderate pulmon-
ary involvement. Bacteria from all MDR-TB patients were
tested for drug-susceptibility and the genotype was deter-
mined by IS6110 DNA fingerprinting and spoligotyping
according with standardized protocols [30, 31]. For drug-
sensitive TB patients included herein, the infecting strain was
not genotyped. Age matched No-TB patients were recruited
at the Laboratorio Central-IHema, Academia Nacional de
Medicina. Written informed consent was obtained according
to Ethics Committee from the institutions. Exclusion criteria
for No-TB patients included positive PPD-test, positive HIV-
test, and familiar/occupational risk of contact with active TB
patients. Inclusion criterion was serum immunoglobulin (Ig)
G on normal reference range (700–1600mg/dL). Among No-
TB patients, 15 had idiopathic neutropenia (age range = 26–
45 yr), 5 had thrombocytopenic disorders (age range = 36–
51), 4 had blood malignant disorders (age range = 30–61 yr),
3 had fungal infection (age range = 35–43 yr), and 3 had
Hepatitis C infection (age range = 25–41 yr).
2.2. Clinical Mtb Isolates. Clinical strains LAM10406 and
H12425 are representative of prevalent LAM and Haarlem
lineages and were obtained from sputum-culture-positive
TB patients. Their genotype, drug-susceptibility, and the in
vitro immune responses were previously described [27]. Cells
were grown in Middlebrook 7H9 broth (Difco Laboratories,
Detroit, MI, USA) at 37∘C in 5% CO
2
until exponential
phase. For immunoassays, bacteria were killed by gamma
irradiation at ≈1550 rads/minute during 27 hours (total
dosage ≥ 2.5 Mrads) (CONEA, Argentina), suspended in
pyrogen-free PBS at OD600 nm = 1 (∼108 bacteria/mL), and
stored at −20∘C until their use.
2.3. Analysis of the Proteomic Profiles of Mtb Strains. Pellets
from 1 litre of 1-month-old cultures grown in Sautonmedium
of each strain were washed, resuspended in cold 1X PBS
pH 7.4, 1mM EDTA, 100X protease inhibitor mix (GE
Healthcare), and disrupted using a Fast Prep FP120 bead-
beater (40 s at 6m s21, using LysingMatrix B).The cell extract
was clarified by centrifugation at 3000×g for 20min and
cell wall proteins were obtained by further centrifugation
at 23000×g for 30min. The supernatant containing the cell
associated proteins was cleaned up with the 2D clean-up
kit from GE Healthcare. Proteins from the cell wall pellet
were obtained by the addition of 2mL buffer (1X PBS pH
7.4, 1mM EDTA, 2% SDS), followed by incubation for 2 h
at 60∘C and centrifugation for 15min at 18000×g. Cell wall
proteins present in the supernatant were then concentrated
and desalted using again the 2D clean-up kit. The protein
pellets were resuspended with rehydration buffer (8M urea,
2% CHAPS, 0.5% IPG buffer pH 4–7, and 20mM DTT),
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and 90 𝜇g protein in a final volume of 450𝜇L was used
to rehydrate a 24 cm immobilized pH 4–7 linear gradient
strip (Immobiline DryStrips, GE Healthcare) for 16 h at
room temperature, following themanufacturer’s instructions.
Isoelectric focusing was carried out with an Ettan IPGphor 3
system (GE Healthcare), using the following programme: 1,
0.5 kVh at 500V; 2, 5.2 kVh (gradient) at 1000V; 3, 13.5 kVh
(gradient) at 8000V; 4, 30 kVh at 8000V. After focus-
ing, the strips were equilibrated for 20min in equilibrium
buffer (2% SDS, 50mM Tris/HCl, pH 8.8, 6M urea, 30%
glycerol, 0.002% bromophenol blue, and 0.5% DTT). The
strips were then overlaid onto 12% SDS-polyacrylamide gels
and, after electrophoresis, proteins were stained with the
silver staining kit (GE Healthcare). Proteins from culture
supernatants of Mtb strains were prepared as described
previously [32] and resolved on 12% SDS-polyacrylamide
gels, which were then stained with colloidal Coomassie (2 g
Coomassie brilliant blue G250 l21; 0.5 g Coomassie brilliant
blue R250 l21; 5% methanol, 42.5% ethanol, 10% acetic
acid).
The differential bands or spots identified were cut from
the gels, digested with modified porcine trypsin (Promega),
and extracted as previously described [33]. Mass spectrome-
try (MS) analysiswas carried out on aBrukerUltraflex IImass
spectrometer, with the matrix a-cyano-4-hydroxycinnamic
acid. Data interpretation and protein identification were per-
formed with theMS/MS spectra datasets using theMASCOT
search algorithm (Version 1.6b9, Matrix Science, available at
http://www.matrixscience.com/).
2.4. RT-qPCR. DNA-free RNA was extracted from 50mL
mid-exponential-phase cultures of strains grown in Middle-
brook 7H9 medium supplemented with 0.05% Tween 80, as
described by Santangelo et al. [34]. DNA-free RNA (1 𝜇g)
was mixed with 50 ng of random primers (Invitrogen) in
a final volume of 20𝜇L and reverse-transcribed to total
cDNA with SuperScript II reverse transcriptase (Invitrogen),
following the manufacturer’s instructions. Identical reactions
lacking reverse transcriptase were also performed to confirm
the absence of genomic DNA in all samples. RT-qPCR was
performed in the Applied Biosystems 7000 DNA sequence
detection system (Perkin-Elmer), with Master Mix Quanti-
Tect SYBR Green (Qiagen), 1 𝜇L of template cDNA, and the
pairs of primers listed in Table S1 in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2014/741309.
Each reaction was performed in duplicate. Results are pre-
sented as ratios calculated with the Relative Expression Soft-
ware Tool (REST@) application described by Pfaffl et al. [35],
based on four biological replicates for in vitro studies. Relative
quantification of each target gene was performed by using
sigA as a reference gene,with real-timePCRefficiencies of tar-
get and reference genes considered as 2. A subsequent test for
significance of the results was performed by using the pair-
wise fixed reallocation randomization test (http://rest.gene-
quantification.info/).
2.5. Recombinant Proteins Expression and Purification. For
immunogenic analyses, the differentially expressed proteins
were cloned as glutathione-S-transferase (GST) fusions using
the Gateway Cloning Technology (Life Technologies, USA).
The genes were PCR amplified using chromosomal DNA
from the strain in which they were identified, with the
primers indicated in Supplementary Table S2 and cloned
in the pENTR Directional TOPO (Invitrogen) to generate
entry clones. LR-recombination reactions were carried out
with LR Clonase II Plus enzyme mix (Invitrogen), following
the manufacturer’s instructions. Reactions were stopped by
addition of Proteinase K and incubation at 37∘C for 10min.
Destination expression vector pDEST15 was obtained from
Invitrogen. The presence of the N-terminal GST tag in
pDEST15 allows purification of recombinant fusion protein
using glutathione agarose. The expression clones generated
were used to transform BL21-AI (Invitrogen) competent cells.
Recombinant E. coli were grown in 500mL LB medium
containing 125 𝜇g ampicillin mL−1 at 37 ∘C. When the OD
600
reached 0.3–0.5, expression of the genes encoding the recom-
binant proteins was induced by addition of L-arabinose
at final concentration of 0.2%. Cells were then harvested
by centrifugation and resuspended in 100mM Tris/HCl,
pH 7.5, 1M NaCl, 20% glycerol, and 1% NP-40. Soluble
cell extracts from the cultures were prepared as described
elsewhere [36] and recombinant proteins were purified
from the supernatants by using Glutathione Sepharose (GE
Healthcare), following the manufacturer’s recommendation.
Since we were not able to solubilize recombinant Rv2241
in the above conditions, its gene was transferred to the
destination vector pDEST17 (Invitrogen) to be expressed as a
His-fusion protein and purified under denaturing conditions
using Urea 8M. In this case the recombinant protein was
purified from the supernatants by using Ni+ resin (Ni-NTA
agarose, Qiagen), following themanufacturer’s recommenda-
tion.
2.6. Indirect ELISAAssays. The following antigens (Ags) were
employed: mannosylated lipoarabinomannan (ManLAM)
from H37Rv strain (kindly provided by J. Belisle, Colorado
State University, Fort Collins, CO, USA); protein purified
derivative (PPD) (Statens Serum Institut, Copenhagen, Den-
mark). Homemade indirect enzyme-linked immunosorbent
assay (ELISA)was used for detection of serumAbs employing
goat anti-human polyvalent (anti-IgA/IgM/IgG) horseradish
peroxidase- (HRP-) conjugated secondary Ab as detection
reagent (Sigma-Aldrich Co. St. Louis, MO, USA). Briefly, 96-
well high binding microplates (Corning, USA) were coated
overnight (ON) at 4∘C with 100 𝜇L of the following Ags: PPD
(1 𝜇g/mL, in CO
3
buffer pH = 9), ManLAM (0.5 𝜇g/mL, in
PO
2
buffer pH = 8), and recombinant proteins (1 𝜇g/mL,
in PBS pH = 7.4). Optimal Ag concentration and coating
buffer was experimentally determined (37, and data not
shown). After properly washing with PBS 0.05% (v/v) tween-
20 (Sigma) and blocking with PBS 2% (v/v) human serum
albumin (HSA) (NatoCor, Co´rdoba, Argentina) plates were
seeded andON incubated at 4∘Cwith serum dilutions: 1/1000
(PPD), 1/800 (ManLAM), and 1/500 (recombinant proteins).
Serum dilutions were established in preliminary assays. Each
sample was tested in duplicate. In assays with recombinant
proteins (Figure 3), unspecific Abs were depleted from sera
by adsorption on plates coatedwith glutathione-S-transferase
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(GST) (1 𝜇g/mL, in PBS pH = 7.4) for 1 h at 37∘C before
serum-Ag incubation step. To deplete Abs directed to surface
exposed Mtb-Ags from sera samples (Figure 5(b)), 150 𝜇L
of 1/500 diluted sera was also preadsorbed with 106 𝛾-irra-
diated H12435 or LAM10406 clinical isolates for 1 h at 37∘C
before serum-Ag incubation step. Finally, secondary reagent
(100 𝜇L, 1/3000 dilution) was added for 30min and, after
extensive washing, HRP activity was measured using tetram-
ethylbenzidine (TMB) substrate (Sigma). Absorbance was
measured at 450 nm (subtracting 570 nm background signal)
using an UVM340 plate reader with DigiRead software (Asys
Hitech, UK).
2.7. Flow Cytometry Assays. Serum Abs directed to surface
exposedMtb-Agswere determined by flow cytometry (FACS)
analysis. Briefly, 106 𝛾-irradiated LAM10406 were incubated
for 30min at room temperature (RT∘) with 1/500 serum dilu-
tion, washed 2 times with PBS-HSA 2% by centrifugation at
800×g for 5min, and stained with anti-human(h)IgM-FITC
(polyclonal goat 𝜇 chain-specific, 1/1000 dilution, Cappel) or
anti-hIgG-PE (mouse monoclonal anti-human Fc-𝛾, 1/600
dilution, Becton Dickinson). Data acquisition of stained
bacteria was performed immediately using log-FSC/log SSC
amplification mode in a FACScan cytometer and CellQuest
software (BD). In order to estimate the isotype of Abs, a
latex bead based FACS assay was employed. Briefly, each
recombinant protein (∼200𝜇g/mL)was passively adsorbed to
latex beads (Ø = 3 𝜇m, 1% v/v, Sigma) by incubating in 3-(N-
morpholino) propanesulfonic acid (MOPS) buffer (40mM,
pH = 6.5) for 3 h at RT∘ with gentle agitation (100 rpm).Then,
protein-coated beads were extensively washed with 2% PBS-
HSA and incubated with 1/400 diluted GST-preadsorbed
serum for 30min at RT∘. Finally, after 2 washings, beads
were stained with anti-hIgM-FITC, anti-hIgG-PE, and anti-
hIgA-FITC (polyclonal goat 𝛼 chain-specific, 1/1000 dilution,
Cappel).
2.8. Data Management, Statistics, and Immunoinformatics.
All figures were edited with Photoshop (Adobe, USA). Excel
(Microsoft, USA) was employed for storage, transformation,
compilation, and edition of data sets and for depicting
the figures’ heat-maps and tables. FACS data analysis was
performed with FCS express 4 (DeNovo Software, CA, USA).
Figures’ graphs and uni/bivariate statistical analyses were
performed using Prism5 (GraphPad, USA) assuming a 𝑃 <
0.05 as significant. SPSS 15.0 (IBM, USA) was employed
for multivariate statistical analysis. Protein structure homol-
ogy models were computed by SWISS-MODEL web server
(SIB, Switzerland) [37]. Best rated protein 3D structure
models were energy relaxed by mean of normal mode-
based molecular dynamics simulations using the NMSim
web server (CPC, Germany) [38]. B-cell epitope predictions
based on crystallographic (Rv0009, Rv0407) or modeled
3D protein structures (Rv2241, Rv2624c) were accessed
with DiscoTope 2.0 server (CBS, Denmark) [39]. PyMOL
(Delano Scientific LLC, USA) was employed to depict pre-
dicted epitopes on each molecule (see Supplementary Table
S3).
3. Results and Discussion
3.1. Identification of Expressed Proteins by LAM10406 and
Haarlem (H) 12425 Clinical Isolates. The rationale behind
searching for differentially expressed proteins between a
strain belonging to LAM and a strain to Haarlem families
was to find proteins that could explain the differential
innate/adaptive immune responses developed by these two
families [26–28]. To identify these proteins we compared the
protein expression patterns of the H12425 and LAM10406
strains by 1D- and 2D-PAGE. In a first approach we prepared
proteins from culture filtrates of both strains and resolved
them by 1D electrophoresis gels, with subsequent colloidal
Coomassie staining. In this case, we identified one differential
band (Figure 1(a)) that was overexpressed in LAM10406.
This band was cut from the gel and trypsin-digested to be
identified by mass spectrometry (MS). Then, we analyzed
the cell wall and cell associated protein fractions by silver-
stained 2D electrophoresis gels. The comparison of two sets
of 2D gels from each strain revealed four proteins present in
the cell wall fraction of LAM10406 and absent in H12425,
one protein from the same fraction present in H12425
and absent in LAM10406 and one protein only present in
the cell associated fraction of LAM10406 (Figure 1(b)). All
these proteins were identified by mass spectrometry and the
results are summarized in Table 1. Although the functions
of the proteins between both strains are diverse, most of
them localize in the cell wall, where they may trigger a
differential host immune response, which could impact the
outcome/progression of the disease.
The differential expression of the genes encoding the
identified proteins was then analyzed by RT-qPCR. Of
the seven proteins, the overexpression of five of them in
LAM10406 could be validated at the transcriptional level
(Figure 2). The regulation in gene expression in the nonva-
lidated cases could occur at a posttranscriptional level.
Then, we analyzed whether the proteins were involved in
the immune response triggered by the two Mtb families. To
this end, we cloned and expressed the RT-qPCR validated
genes in Escherichia coli, by using the Gateway technology.
Since one of the validated genes failed our attempt at PCR
amplification (Rv1223), we continued working only with
the remaining four proteins (Rv2624c, Rv0009, Rv0407, and
Rv2241). All the proteins were cloned as GST fusions with
the exception of Rv2241, which was expressed as a His-fusion
protein and purified under denaturing conditions because of
its insolubility under other conditions.
3.2. Rv2241, Rv0407, Rv2624c, and Rv0009 Induce Antibody
Responses on Subsets of Drug-Sensitive and MDR-TB Patients.
Purified recombinant proteins were used as coating antigens
for serum ELISA assays. As shown in Figure 3(a), circulating
Abs against all these proteins were detected in subsets of TB
patients. Anti-Rv2241 Abs were the more frequently found
(∼54%), followed by anti-Rv0407 (∼43%), anti-Rv2624c
(∼35%), and anti-Rv0009 (∼32%). Receiver operating charac-
teristic (ROC) analysis demonstrated that immune reactivity
against all of these proteins can statistically distinguish the
TB patient population from the No-TB population (Rv2241:
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Figure 1: Proteomics to identify differential proteins between LAM10406 and H12425M. tuberculosis strains. (a) Equal amounts of proteins
from culture supernatants of Mtb LAM10406 and H12425 were resolved on 1D 12% polyacrylamide gels, which were stained with colloidal
Coomassie. The identified differential protein is indicated with the arrow. (b) Differential proteins identified by 2D gel electrophoresis. The
first-dimension isoelectric focusing used a pH range of 4–7. The second-dimension SDS-PAGE was on 12% polyacrylamide gels, which were
silver stained.Differential proteins present in the cell wall and cell-associated fractions of theMtbLAM10406 andH12425 strains are indicated.
Table 1: Differentially expressed proteins betweenM. tuberculosis LAM10406 andM. tuberculosisH12425 identified by 1D and 2D gels.
Rv number Gene symbol Description∗ Cellular localization Strain in which it isoverexpressed
Rv2624c None Conserved hypothetical protein Cell wall LAM10406
Rv0382c pyrE Probable orotatephosphoribosyltransferase PyrE Cell wall LAM10406
Rv0009 ppiA Probable iron-regulated peptidyl-prolylcis-trans- isomerase A PpiA Cell wall LAM10406
Rv0407 fgd1 Probable F420-dependentglucose-6-phosphate dehydrogenase Fgd1 Cell wall LAM10406
Rv1144 None Probable short-chain typedehydrogenase/reductase Cell wall H12425
Rv1223 htrA Probable serine protease HtrA Cell associated LAM10406
Rv2241 aceE Probable pyruvate dehydrogenase E1component AceE Culture supernatant LAM10406
∗According to TubercuList (http://genolist.pasteur.fr/TubercuList/).
𝑃 < 0.0001; Rv0407: 𝑃 < 0.0002; Rv2624c: 𝑃 < 0.0006;
Rv0009: 𝑃 < 0.0073). However, regarding clinical value
of these Ags in serological diagnosis of pulmonary TB,
only Rv2241 exhibited a moderate performance (% area
under ROC curve ≥ 85%, Figure 3(b)). Besides, we did not
find significant association between drug-susceptibility status
(drug-sensitive TB versus MDR-TB), Mantoux test (PPD+++
versus PPD+ versus PPDneg), and the pulmonary involvement
(Moderate versus Severe) with seroreactivity for any of the
selected proteins (𝑃 > 0.05; 𝜒2-tests with Yates’ correction).
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Figure 2: Gene expression fold-change differences between
LAM10406 and H12425 using RT-qPCR. Relative gene expression
was calculated using the 2-ΔΔCt method with E correction, using
sigA mRNA expression as reference genes and H12425 as the
calibrator. Data were analyzed using a random permutation test
( ∗𝑃 < 0.05). The bars indicate the average ratios of LAM10406/
H12425 ± SD.
Interestingly, according to the interrogation of a database
that contains published epitopes (http://www.iedb.org/; our
last query = 5/23/14), none of the above indicated proteins
have been previously reported as immunogenic/antigenic
with the exception ofRv2241. Particularly, two 9-mer peptides
present in Rv2241 sequence bind with high affinity to human
HLA-I molecules [40], which potentially can induce T-cell
dependent immune responses.
In terms of signal-to-noise ratio of ELISA assays, strong
differences among each recombinant protein were detected.
Given that this may affect accuracy and sensitivity of the test,
we evaluated if protein specific characteristics might account
for such differences.The theoretical range of Ab binding sites
per well was estimated (see Supplementary Table S3). For this
purpose several factors were considered: protein structure-
based immunoinformatic predictions, the saturating protein-
binding capacity of microplates, and the molecular weight
(Mw) of the recombinant fusion proteins. As it is shown in
Figure 3(c), a positive correlation between predicted epitope
density for a given recombinant protein and its corresponding
positive ELISA signal was verified (OD450 nm–570 nm values
from seropositive samples). This result suggests that struc-
tural characteristics of the proteins may explain variations in
the signal/noise ratio output. Furthermore, this result may be
useful for introducing technical improvements to the assay.
Having observed that Rv2241, Rv0407, Rv2624c, and
Rv0009 are augmented at mRNA and protein levels in axenic
cultures of LAM10406 strain (Table 1), we wondered whether
an association between Abs against these proteins in sera
from TB patients and the infecting strain could be detected.
To assess this we must restrict our analysis to MDR TB
patients given that genotyping data of infecting strains for
drug-sensitive TB patients were not available. Interestingly,
all patients infected with non-LAM strains (Haarlem 𝑛 =
7; Tuscani 𝑛 = 1) were seroreactive against at least one
recombinant protein. On the other hand, only two samples
among LAM-infected patients (𝑛 = 10) were seroposi-
tive (Table 2). These results showed a statistical association
between non-LAM infections and immunoreactivity (𝑃 =
0.0035;𝜒2-tests with Yates’ correction), which is in contrast to
the presumption expected. Any possible explanation behind
these apparently conflicting data could only be achieved after
analyzing a greater number of locally circulatingMtb strains
at proteomic level and a larger serological survey that should
include not only MDR-TB patients but also drug-susceptible
TB patient infected with known lineage strains.
3.3. Antibody Responses against Rv2241, Rv0009, Rv0407,
and Rv2624c Are Mutually Correlated but Independent of
the Presence of Anti-PPD or Anti-ManLAM Antibodies. One
interesting observation from Table 2 is the abundance of
MDR-TB patients’ sera that react with more than one recom-
binant protein. In order to test if cross-reactivity is confined
to recombinant proteins and if it is a specific feature of
MDR-TB patients, we extended our analysis to other Mtb-
Ags and to drug-sensitive TB patients. As can be observed
in (Figure 4(a)), a strong correlation in Ab titers among
each of the recombinant proteins was observed, but not with
PPD or ManLAM Ags. Next, we tested if IgM and IgG Abs
that bindMtb-cell surface exposed structures were correlated
with those directed to recombinant proteins. As it is shown
in Figure 4(b), Ab titers against proteins correlated with
anti-Mtb IgM but not with anti-Mtb-IgG. By multivariate
based hierarchical classification, we concluded that Rv0407,
Rv0009, Rv2624c, Rv2241, andMtb-IgMAgsmay be clustered
together as function of their seroreactivity (Figure 4(c)).
Analyses of antigen recognition by individual sera revealed
that the pattern of antigens reacting with serum Abs varied
greatly from patient to patient; thereby, no clear division
among patients with MDR versus drug-sensitive as well as
with bacillary loads was observed (Table 2).
3.4. Isotype Analysis of Anti-Rv2241, Rv0009, Rv0407, and
Rv2624c Antibodies. The functionality of Abs is largely deter-
mined by the specific interaction of their constant fragment
(Fc) domain with host cell Ig receptors. To better describe the
circulating populations of anti-Rv2241, Rv0009, Rv0407, and
Rv2624c Abs, we performed an immunoisotype characteriza-
tion based on an Ag-specific FACS analysis [41]. To do this,
sera reactive against all the recombinant proteins (𝑛 = 10)
were incubated with recombinant protein-coated latex beads
(Figure 5(a)). Because different structural features of proteins
may affect latex bead coating efficiency as well as the employ-
ment of different fluorescent-labeled secondary reagents, this
assay only allows vertical comparisons (between patients).
However, within a given isotype group, Rv0009-specific IgM
and Rv2241-specific IgA tended to be more abundant than
the others. Besides, we were able to compare two samples
from the same TB patient, one taken early when he was
impatient (MDR11.1) and the other taken later on when
the clinical symptoms declined at the moment of hospital
discharge (MDR11.2). We observed that the diminution
in Rv2241-specific IgM and IgA was accompanied by an
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Figure 3: Antibodies against Rv2241, Rv0009, Rv0407, and Rv2624c recombinant proteins in drug-sensitive and MDR-TB patients’ sera.
ELISA plates were coated with recombinant proteins, loaded with 1/500 serum dilutions, and reveled with HRP conjugated anti-human
polyvalent IgM/A/G. (a) 1D scatter plots indicating serological results of No-TB (No TB, 𝑛 = 31), drug-sensitive TB (S TB, 𝑛 = 19), and
multi-drug-resistant TB (MDR TB, 𝑛 = 18) patients’ sera. Threshold, defined by maximum likelihood ratio (ROC analysis), was shaded in
gray. Seropositive samples for each protein were color highlighted (Rv2241 = red, Rv0009 = purple, Rv0407 = blue, and Rv2624c = green).
(b) ROC analysis indicating area under curve ± 95% CI. (c) Correlation analysis between signals (mean ± SEM) of positive samples versus
immune-informatics predicted epitope density (median ± range) for each recombinant protein.
increase in Rv2241-specific IgG, which is consistent with a
class-switching event. However, these observations will need
further confirmation in more extended studies.
3.5. Mtb-Surface Accessibility of Rv2241, Rv0009, Rv0407, and
Rv2624c Antigenic Determinants. The outcome of mycobac-
terial infections is thought to be critically dependent on
the nonopsonic invasion and colonization of macrophages
during primary infection of inhaled bacteria. Indeed, if
Mtb is opsonized by cell wall specific Abs, it becomes
more susceptible to microbicidal action of phagocytes and
complement system [42]. Herein, we observed that Mtb-
surface binding IgMwas correlated with Abs against Rv0009,
Rv0407, Rv2624c, and Rv2241 (Figure 4(b)) and that, exclud-
ing the later, the three are Mtb cell wall associated proteins
(Table 1). Given these results, we assessed if the Abs that
recognized those proteins were also able to bind surface-
exposed structures onwhole bacilli. For this purpose, selected
seropositive samples were preadsorbed with clinical isolates
(LAM10406 andH12425) or mock preadsorbed (HSA-coated
Latex Beads) before ELISA assay. In order to show that this
indirect assay is sufficiently sensitive to reveal the presence
of anti-surface Abs that also bind to a given Ag, we employed
ManLAM, awell characterizedMtb-cell surface, that exposed
Ag as positive control. We observe that preadsorption of
anti-ManLAM-positive sera (𝑛 = 6) with both clinical
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Figure 4: Cross-reactivity analysis of humoral immune responses in drug-sensitive and MDR-TB patients’ sera. (a) 2D scatter plots of
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correlation test was applied after verification of normal distribution of all data sets. “ns” indicates 𝑃 > 0.05. Thresholds are delimited by
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Figure 5: Characterization of anti-Rv2241, Rv0009, Rv0407, and Rv2624c antibodies from seropositive patients. (a) Isotype characterization
of anti-Rv2241, Rv0009, Rv0407, and Rv2624c binding Abs was performed by FACS analysis using latex bead as Ag adsorbing solid support.
For data normalization, MFI values of seropositive TB patients (𝑛 = 10 + 1 repeated sample/MDR11.2) were divided by MFI values of a
No-TB patient (No TB1). Matrix of values was represented as heat-map. (b)Mtb-cell surface recognition by anti-Rv2241, Rv0009, Rv0407, and
Rv2624c Abs was evaluated by preadsorbing seropositive (𝑛 = 11) samples with 𝛾-irradiated whole LAM10406 and H12425Mtb cells or with
HSA-Latex Beads (negative binding control) before incubation step of ELISA assay. Results were presented as ratio betweenMtb preadsorbed
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Table 2: Immunoreactivity of TB MDR patients infected with Haarlem, LAM, and TuscaniMtb lineages.
Patient data Serology2
Code Sex Age SPT family1 BAAR Rv2241 Rv0407 Rv0009 Rv2624c
MDR18 F 24 Haarlem + +++ +++ +++ +
MDR5 F 35 Haarlem − +++ ++ + ++
MDR19 M 28 Haarlem +++ ++ ++ ++ +
MDR11 M 28 Haarlem + + +++ + +
MDR2 F 44 Haarlem + + + ++ +
MDR3 F 47 Haarlem + + + ++ −
MDR14 F 35 Haarlem − − + − −
MDR8 F 27 Tuscani − − − − +
MDR10 F 23 LAM + +++ +++ +++ +++
MDR9 F 20 LAM − ++ ++ +++ +
MDR6 M 49 LAM − − − − −
MDR12 M 28 LAM − − − − −
MDR17 F 46 LAM +++ − − − −
MDR7 F 36 LAM + − − − −
MDR13 M 24 LAM +++ − − − −
MDR4 F 40 LAM + − − − −
MDR16 F 48 LAM +++ − − − −
MDR1 F 42 LAM + − − − −
1For each MDR TB patient, genotype of infecting strain was assessed by standard spoligotyping methods [30, 31]. 2The relative OD values among seropositive
samples are represented by “+++” (high OD values), “++” (mid OD values) and “+” (low OD values). Seronegative samples are indicated by “−” (OD values
below cutoff measure).
Mtb isolates reduced the specific binding to ManLAM when
compared with mock preadsorbed samples (Figure 5(b)). By
contrast, Ab depletion by preadsorption of 11 antiprotein
positive sera with bothMtb strains was not able to reduce the
immunoreactivity against nonrecombinant protein (Figure
5(b)). Altogether, the above results indicate that surface-
exposed epitopes on LAM10406 and H12425 cells were not
efficiently/sufficiently recognized by anti-Rv0009, Rv0407,
and Rv2624c Abs, suggesting that these Igs have limited or
null Mtb-opsonic capacity. Moreover, we observed the same
results when we tested anti-Rv2241 Abs, which are expected
to bind secreted epitopes (Table 1).
4. Conclusions
Based on the comparison of two locally circulating Mtb
clinical isolates that exhibited divergent stimulatory proper-
ties on human leukocytes [27–29], herein we identify seven
differentially expressed proteins. Four of these proteins were
overexpressed in cultures of LAM10406 strain and they are
able to induce humoral immune response in the human host
during natural infection. Unexpectedly, when the infecting
genotype was correlated with serology, a higher proportion
of seropositive cases among patients infected with no LAM-
strains were observed. Interestingly, those TB patients that
exhibit seroreactivity against one protein also show sub-
stantial cross-reactivity against the others, suggesting that
these proteins are coexpressed during infection. However, in
order to be confirmed, extended, and/or explained, all these
interesting observations will require further studies involving
a greater number of clinical isolates fromdifferent linages and
a more representative cohort of TB patients.
Rv2241 was the most immunogenic protein studied,
with some potential in terms of practical application as
biomarker. Interestingly, Rv2241 is a secreted protein, a fea-
ture that has been previously highlighted regarding humoral
immune responses in human TB [21–24]. On the other hand,
the specific Abs against the cell-wall associated proteins
Rv0407, Rv2624c, and Rv0009 seem to have low opsonic
capacity, which might be ascribed to the complex struc-
ture and chemical composition of the mycobacterial cell
wall.
Additionally, given that in serological studies the bioin-
formatics approaches are only marginally used, we consider
that the successful application of a B-cell epitope prediction
tool to explain our experimental outputs is per se an interest-
ing finding. For example, similar strategies may be followed
during rational design of more sensitive Ag-immobilized
based immunoassays.
The humoral immune response in human TB has been
shown to be highly variable and strongly influenced by
multiple factors. This reinforces the idea that combination
of classical immunochemical assays withmodern approaches
can give a better understanding of such complexity. In this
line, the present studymakes use of the information provided
by genetic, proteomic, and immunoinformatic outputs in
order to contextualize the noisy data that come from sero-
logical analysis of TB patients.
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